Author： Vey Norbert
Publisher： Informa Healthcare
ISSN： 1465-6566
Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.3, 2004-03, pp. : 613-621
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The impressive activity of arsenic trioxide in acute promyelocytic leukaemia (APL) has renewed the interest in this old compound. Arsenic trioxide targets the sulfhydryl groups present in many proteins involved in oncogenesis and has a broad spectrum of biological activities. This article will review the mechanisms of action of the drug and their relevance to the treatment of myelodysplastic syndrome (MDS), a disease for which no standard treatment currently exists. The early clinical experience has confirmed the activity of arsenic trioxide in MDS. The preliminary results of ongoing Phase II studies conducted in patients with MDS suggest that arsenic trioxide produces haematological improvement including durable transfusion independence in ∼ 30% of patients. The current data are presented and discussed in this review.
Related content
Lenalidomide for Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. :
Access to resources
Recommend
Arsenic trioxide in the treatment of haematological malignancies
Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. :